EX-10.23
from S-1
47 pages
Purchase Agreement This Purchase Agreement (“Agreement”) Is Made and Entered Into on December 9, 2019 (“Effective Date”), by and Between Generex Biotechnology Corporation, a Delaware Corporation (“Company”), and the Investor Whose Name Appears on the Signature Page Hereto (“Investor”). Recitals A. the Parties Desire That, Upon the Terms and Subject to the Conditions Herein, Investor Will Purchase for $2,000,000.00 Shares of Common Stock and a Promissory Note That May Become Convertible Into Common Stock; and B. the Offer and Sale Provided for Herein Are Being Made Pursuant to the Exemptions From Registration Under Section 4(a)(2) of the Act as a Transaction by an Issuer Not Involving Any Public Offering, and as a Private Placement Pursuant to Rule 506 of Regulation D. Agreement in Consideration of the Foregoing, the Receipt and Adequacy of Which Are Hereby Acknowledged, Company and Investor Agree as Follows: I. Definitions. in Addition to the Terms Defined Elsewhere in This Agreement and the Transaction Documents, Capitalized Terms That Are Not Otherwise Defined Have the Meanings Set Forth in the Glossary of Defined Terms Attached Hereto as Exhibit 1. II. Purchase and Sale
12/34/56
EX-10.21
from S-1
32 pages
Equity Purchase Agreement This Equity Purchase Agreement (This “Agreement”) Is Entered Into as of December 6, 2019 (The “Execution Date”), by and Between Generex Biotechnology Corporation, a Delaware Corporation (The “Company”), and Oasis Capital, LLC, a Puerto Rico Limited Liability Company (The “Investor”)
12/34/56